Indegene Limited

rs,

INDGN/SE/2025-26/09 April 28, 2025 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172 Dear Sir / Madam, National Stock Exc

56%

nsultancy services across value chain Regulatory submissions Risk management Health economics 56% Enterprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solution

12%

egulatory submissions Risk management Health economics 56% Enterprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analyt

28%

nagement Health economics 56% Enterprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analytics and Gen AI © 2025 Indegen

4%

terprise Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analytics and Gen AI © 2025 Indegene. All rights reserved. (1) Revenu

rs1

Commercial Solutions1 12% Omnichannel Activation1 28% Enterprise Medical Solutions1 4% Others1 Technology, Data, Analytics and Gen AI © 2025 Indegene. All rights reserved. (1) Revenue contribut

14%

r TAM Lifesciences at Inflection Point We Offer Solutions Across Life Sciences End Markets ~9-14% CAGR (2022-2026) in Outsourcing Operations Across Verticals Patent Cliff Large number of drugs a

93.8%

efficiency and strategy by large biopharma for commercialization of existing pipeline Biopharma 93.8%(1) Medical Devices 2.6%(1) Emerging Biotech 2.5%(1) © 2025 Indegene. All rights reserved. (1) I

2.6%

by large biopharma for commercialization of existing pipeline Biopharma 93.8%(1) Medical Devices 2.6%(1) Emerging Biotech 2.5%(1) © 2025 Indegene. All rights reserved. (1) Indicates revenue contribu

2.5%

mmercialization of existing pipeline Biopharma 93.8%(1) Medical Devices 2.6%(1) Emerging Biotech 2.5%(1) © 2025 Indegene. All rights reserved. (1) Indicates revenue contribution by customer industry

1.1%

All rights reserved. (1) Indicates revenue contribution by customer industry for FY25. Remaining 1.1% from other industry. 5 Management Commentary on Q4FY25 results Manish Gupta Chairman and Chief

4.9%

ancial Officer “We sustained our profitable growth momentum in Q4FY25, clocking revenue growth of 4.9% QoQ, buoyed by recent deal wins from the last 2 quarters. We continued the momentum on deal wins t

Notes

1

Notes

1. 2. 3. 4. Active clients are clients from whom the Company have earned $0.25 million or more in revenues for the last twelve months preceding the relevant date. Based on INR revenue. YoY growth for quarter Mar 31, 2024, based on unaudited financials. Earnings before interest, taxes, depreciation and amortization (“EBITDA”) represents profit/(loss) for the period before income tax expense, finance costs, depreciation and amortization expense, interest income and any exceptional items. Net Retention Rate (NRR) is based on USD revenues earned in current year from previous year’s active customers as a percentage of revenues earned in previous year from previous year’s active customers. Revenue by service offering (in %) Particulars Enterprise Medical Solutions Enterprise Commercial Solutions Omnichannel Activation Others Total Quarter ended (contribution) Growth Mar 31, 2025 Dec 31, 2024 Mar 31, 2024 27.9 56.3 12.8 3.0 28.5 55.6 12.4 3.5 23.8 58.3 13.1 4.8 100.0 100.0 100.0 YoY 31.5 8.4